Advertisement

Topics

Roche gains CHMP positive opinion for RoACTEMRA for children living with a rare form of arthritis in Europe

07:30 EDT 26 Apr 2013 |

Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for RoACTEMRA (tocilizumab) for the treatment of polyarticular juvenile idiopathic arthritis (PJIA) in patients two years of age or older who have responded inadequately to previous treatment with methotrexate (MTX). RoACTEMRA, known as ACTEMRA outside Europe, can be given alone or in combination with MTX in people with PJIA.

Original Article: Roche gains CHMP positive opinion for RoACTEMRA for children living with a rare form of arthritis in Europe

NEXT ARTICLE

More From BioPortfolio on "Roche gains CHMP positive opinion for RoACTEMRA for children living with a rare form of arthritis in Europe"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Arthritis
Arthritis is by definition the inflammation of one or more joints, characterized by swelling, pain, warmth, redness and diminished range of joint movement (Oxford Medical Dictionary). There are many different types; Noninflammatory; Osteoarthritis, N...